CA
NZ
UK
AU
IND
US
The investment reflects UPS's strategic pivot toward higher-margin specialised healthcare logistics at a time when parcel volume growth in the broader e-commerce segment has moderated. GLP-1 therapies have generated unprecedented prescription volumes over the past two years, creating structural demand for pharmaceutical cold chain …
Definium Therapeutics, Inc. (NASDAQ:DFTX), formerly Mind Medicine, closed sharply higher after reporting positive topline results from the Phase 3 Emerge study of DT120 in adults with major depressive disorder.
REGENXBIO Inc. (NASDAQ: RGNX) announced Monday that it has reached alignment with the FDA on the regulatory pathway for potential accelerated approval of NAVSUNLI, its one-time gene therapy for Mucopolysaccharidosis II. Shares surged more than 14% to $8.92, with the stock reaching an intraday …
Achieve Life Sciences, Inc. (NASDAQ: ACHV) announced Monday that it has received a Complete Response Letter from the FDA regarding the cytisinicline New Drug Application for smoking cessation. Shares rose roughly 7.6% to $5.22, reflecting market relief that the FDA's feedback was confined entirely …
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.
AbbVie (NYSE: ABBV) announced U.S. FDA approval for Skinvive by Juvederm, a novel hyaluronic acid injectable for neck wrinkles, alongside updated Phase 3 data demonstrating durable efficacy in chronic lymphocytic leukemia.Key HighlightsAbbVie (NYSE: ABBV) received FDA approval for Skinvive by Juvederm, the first hyaluronic …
Codexis (NASDAQ: CDXS) shareholders finalized their annual meeting decisions, endorsing the company’s proposed board of directors without dissent. The vote reaffirms investor alignment with management’s long-term strategy in the biocatalysis sector. The outcome removes near-term governance uncertainty for the biotech firm.
Enliven Therapeutics has captured investor attention with its experimental oncology treatments, which aim to address unmet needs in rare and aggressive cancers. The company’s focus on precision medicine has fueled optimism, though its programs remain in early-stage testing. Progress in these trials has contributed …
Nuvectis Pharma revealed plans to broaden its therapeutic portfolio through a strategic in-licensing deal targeting complement-mediated diseases and oncology. The announcement came during a corporate update call, where leadership emphasized the company’s shift toward high-potential disease areas with limited treatment options. This licensing push …
Summit Therapeutics (NASDAQ: SMMT) stands as a high-volatility biotech stock with a singular focus on its clinical pipeline. The company’s binary outcome structure means its valuation hinges on the success or failure of key drug development milestones. This profile attracts investors comfortable with elevated …
Please wait processing your request...